Business
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of
About this update from Novocure Limited
[{"type":"text","content":" ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven solid tumor types confirms the anti-mitotic effect of Tumor Treating Fields and further explores downstream effects to identify optimal use of Tumor Treating Fields, including the role of Tumor Treating Fields-induced immunogenic cell death.\n\nPresentation highlights include research showing the induction of robust anti-tumor immunity by Tumor Treating Fields in glioblastoma, the immunoregulatory role of Tumor Treating Fields on macrophage polarization, the effects of Tumor Treating Fields on DNA damage repair, and replication stress as a pathway to illuminate novel combination therapy options.\n\n“Ongoing research at Novocure and throughout the global scientific community continues to build upon and deepen our understanding of Tumor Treating Fields as we strive to extend survival in some of the most aggressive forms of cancer,” said Dr. Uri Weinberg, Novocure’s Chief Science Officer. “We are honored to be a part of the invaluable exchange of scientific information at the AACR Annual Meeting and are particularly pleased to see an increasing focus on the effect of Tumor Treating Fields on the immune system’s response against cancer.”\n\nPresentations from Novocure-sponsored and partner programs include:\n\n(Poster #: CT258) EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma. W. Shi (Clinical Trials)\n\n(Poster #: LB064) Long-term application of TTFields in anaplastic astrocytoma – a case study. D. Markovic (Clinical Research)\n\n(Poster #: 2635) Contemporary clinical practice guidelines for the management of glioblastoma: an international survey. A. Lawson McLean (Science and Health Policy)\n\n(Poster #: 1065) Concomitant dexamethasone treatment and tumor treating fields induced cell death in glioblastoma. B. Linder (Combination Therapies)\n\n(Poster #: 2634) French health utilities for patients with glioblastoma using TTFields. G. Chavez (Science and Health Policy)\n\n(Poster #: 717) Rapid transfo...